HealthXL Webinar: Unlocking the Value of Digital Measures in Drug Development

Digital measures have the potential to revolutionise drug development, however, pharma has been slow to fully utilise these measures due to their high costs and lack of standardised applications across therapeutic areas. Experts also believe that a lack of patient and HCP awareness as well as a shortage of technical expertise is currently holding the industry back. 

In a nutshell, we require industry collaborations in order to usher in a new era of medicine. The industry's pursuit of optimised drug development should incentivise the use of digital measures in both clinical trials and real-world applications. Stakeholders need to work together through industry consortiums, regulatory standardisation, and the sharing of validation data to expand the use of digital measures in clinical development.  

So, how can we come together to ensure better utilisation of digital measures in clinical trials? 

Join the HealthXL community as we deep dive into this topic using our panel's expertise and insights from our latest report on the subject. We’ll discuss: